OVERVIEW

Advances in the Treatment of Renal Cell Carcinoma is organized by Med-IQ and will be held from Oct 11, 2018 - Oct 10, 2019.

Target Audience:
This activity is intended for oncologists.

Accreditation/Designation Statements:
Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Need:
The annual American Society of Clinical Oncology (ASCO) meeting showcases cutting-edge research on treatment modalities and new therapies in the field of oncology. It is important for oncologists who manage patients with renal cell carcinoma (RCC) to be aware of data presented at ASCO 2018 on the effectiveness of RCC treatment strategies, including cytoreductive nephrectomy and radiation therapy, and emerging biomarkers to predict immunotherapy response in patients with RCC.

Learning Objectives:
Upon completion, participants should be able to:
• Identify patients with metastatic renal cell carcinoma who may benefit from cytoreductive nephrectomy
• Discuss the impact of adjuvant sorafenib on outcomes in oligometastatic renal cell carcinoma patients.